The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
CGTG-102 (Ad5/3-D24-GMCSF), a novel oncolytic adenovirus, in patients with refractory solid tumors: Experience from an advanced therapy access program.
Mikael Von Euler
Employment or Leadership Position - Oncos Therapeutics
Stock Ownership - Oncos Therapeutics
Research Funding - Oncos Therapeutics
Other Remuneration - Oncos Therapeutics
Anna Kanerva
Employment or Leadership Position - Oncos Therapeutics (I,U)
Consultant or Advisory Role - Oncos Therapeutics (I)
Stock Ownership - Oncos Therapeutics (B)
Research Funding - Oncos Therapeutics (I)
Other Remuneration - Oncos Therapeutics (I)
Petri Nokisalmi
No relevant relationships to disclose
Anniina Koski
Research Funding - Oncos Therapeutics
Iulia Diaconu
Stock Ownership - Oncos Therapeutics
Vincenzo Cerullo
Stock Ownership - Oncos Therapeutics
Timo K. Joensuu
No relevant relationships to disclose
Minna Oksanen
No relevant relationships to disclose
Sari Pesonen
Stock Ownership - Oncos Therapeutics
Lotta Kangasniemi
Employment or Leadership Position - Oncos Therapeutics
Stock Ownership - Oncos Therapeutics
Research Funding - Oncos Therapeutics
Tuuli Ranki
Employment or Leadership Position - Oncos Therapeutics
Stock Ownership - Oncos Therapeutics
Research Funding - Oncos Therapeutics
Raita Heiskanen
Employment or Leadership Position - Oncos Therapeutics
Akseli Hemminki
Employment or Leadership Position - Oncos Therapeutics (U)
Consultant or Advisory Role - Oncos Therapeutics
Stock Ownership - Oncos Therapeutics (B)
Research Funding - Oncos Therapeutics
Other Remuneration - Oncos Therapeutics